• Dermata Therapeutics held its annual shareholder meeting on May 27, 2026.
• Shareholders authorized an amendment to the 2021 Omnibus Equity Incentive Plan, lifting the share pool to 402,214 shares.
• Investors also backed the planned issuance of common stock underlying certain warrants tied to a December 23, 2025 securities purchase agreement.
• Approval was also granted to reprice warrants exercisable for up to 120,734 common shares.
• CBIZ CPAs was ratified as independent auditor for the year ending Dec. 31, 2026; an adjournment proposal was also approved.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Dermata Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001493152-26-025441), on May 27, 2026, and is solely responsible for the information contained therein.